Hennion & Walsh Asset Management Inc. Buys 10,799 Shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY)

Hennion & Walsh Asset Management Inc. lifted its position in shares of Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) by 14.4% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 85,871 shares of the company's stock after purchasing an additional 10,799 shares during the period. Hennion & Walsh Asset Management Inc. owned about 0.15% of Harmony Biosciences worth $2,850,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. Barclays PLC grew its stake in Harmony Biosciences by 110.9% during the third quarter. Barclays PLC now owns 76,862 shares of the company's stock worth $3,074,000 after purchasing an additional 40,416 shares during the period. Janney Montgomery Scott LLC boosted its holdings in shares of Harmony Biosciences by 9.8% during the 4th quarter. Janney Montgomery Scott LLC now owns 17,445 shares of the company's stock worth $600,000 after buying an additional 1,550 shares in the last quarter. KBC Group NV grew its position in shares of Harmony Biosciences by 79.9% during the 4th quarter. KBC Group NV now owns 1,844 shares of the company's stock worth $63,000 after buying an additional 819 shares during the period. Yousif Capital Management LLC grew its position in shares of Harmony Biosciences by 22.4% during the 4th quarter. Yousif Capital Management LLC now owns 14,325 shares of the company's stock worth $493,000 after buying an additional 2,622 shares during the period. Finally, State of Alaska Department of Revenue increased its stake in shares of Harmony Biosciences by 26.3% in the 4th quarter. State of Alaska Department of Revenue now owns 21,716 shares of the company's stock valued at $747,000 after acquiring an additional 4,526 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company's stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on HRMY shares. Oppenheimer started coverage on Harmony Biosciences in a research report on Monday. They issued an "outperform" rating and a $61.00 target price for the company. UBS Group decreased their price objective on Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a report on Monday, April 28th. Mizuho upped their target price on Harmony Biosciences from $44.00 to $48.00 and gave the stock an "outperform" rating in a research report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft initiated coverage on Harmony Biosciences in a report on Tuesday, February 11th. They issued a "buy" rating and a $55.00 target price on the stock. Finally, Needham & Company LLC restated a "buy" rating and set a $49.00 price target on shares of Harmony Biosciences in a research note on Tuesday, May 6th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average price target of $53.00.

Harmony Biosciences Stock Down 0.4%

Shares of HRMY traded down $0.13 on Thursday, reaching $35.03. The stock had a trading volume of 502,597 shares, compared to its average volume of 614,412. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences Holdings, Inc. has a 12-month low of $26.47 and a 12-month high of $41.61. The firm has a market capitalization of $2.01 billion, a price-to-earnings ratio of 16.60, a price-to-earnings-growth ratio of 0.47 and a beta of 0.87. The company has a 50-day simple moving average of $31.70 and a 200-day simple moving average of $34.03.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its earnings results on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm had revenue of $184.73 million during the quarter, compared to analyst estimates of $184.26 million. During the same period last year, the business earned $0.67 earnings per share. The business's revenue was up 19.5% on a year-over-year basis. Sell-side analysts predict that Harmony Biosciences Holdings, Inc. will post 2.43 EPS for the current year.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.